Table 1.
Participant characteristics.
| Characteristics | All participants |
|---|---|
| No. of study participants | 321 |
| Age, years | 69.60 (7.99) |
| No. of females (%) | 180 (56.07) |
| No. of ApoE4 carriers (%)a | 79 (24.61) |
| Education, year | 11.54 (4.69) |
| MMSE score (maximum, 30) | 25.92 (3.35) |
| GDS score (maximum, 30) | 5.53 (5.33) |
| MCI, no. (%) | 67 (20.87) |
| CA score (maximum, 5) | |
| Early life | 2.24 (0.69) |
| Midlife | 2.37 (0.82) |
| Late life | 2.57 (0.73) |
| Global cerebral Aβ deposition, SUVR | 1.28 (0.37) |
| Aβ positivity (%) | 68 (21.18) |
| AD-CMglu, SUVR | 1.39 (0.13) |
| AD-ND positivity (%) | 151 (47.04) |
APOE4, apolipoprotein E ε4; MMSE, Mini-Mental State Examination; GDS, Geriatric Depression Scale; MCI, mild cognitive impairment; CA, cognitive activity; Aβ, amyloid-beta; SUVR, standardized uptake value ratio; AD-CMglu, Alzheimer’s disease signature region cerebral glucose metabolism; AD-ND, AD-signature region neurodegeneration. Data are presented as mean (SD) unless otherwise indicated. aApoE4 carriers are the percentage of individuals with at least one APOE4 allele.